Departments of Pathology, Northwestern Memorial Hospital, 251 E. Huron St., Chicago, IL 60611-2908, USA.
Arch Pathol Lab Med. 2010 Jul;134(7):1024-8. doi: 10.5858/2009-0300-OA.1.
Differentiating ductal carcinoma in situ (DCIS) from lobular carcinoma in situ (LCIS) on core biopsy has important clinical implications. Lobular carcinoma in situ variants, including LCIS with necrosis and pleomorphic LCIS, share morphologic features with solid DCIS that may lead to misclassification.
(1) To review all LCIS variants diagnosed in core biopsies at Northwestern University, Feinberg School of Medicine, and determine the frequency of misinterpretation of variant LCIS as solid DCIS in archival core biopsies, and (2) to determine the frequency of upgrade to invasive carcinoma or DCIS in the surgical excision.
Consecutive core biopsies with original diagnoses of predominantly solid DCIS without invasion that were performed between January 2001 and December 2005 at Northwestern University, Feinberg School of Medicine, were selected for E-cadherin staining. The revised diagnosis of LCIS was based on E-cadherin negativity and morphology. The frequency of LCIS variants upgraded was then estimated from all core biopsies with original or revised diagnoses of pleomorphic LCIS or LCIS with necrosis.
Among 75 cases of solid DCIS, 10 (13.3%) were reclassified as LCIS, including 9 variants (5 pleomorphic LCIS, 4 LCIS with necrosis) and 1 classic LCIS. Twenty-eight patients comprised the entire group of LCIS variant cases (both reclassified and originally diagnosed cases). Seven patients with LCIS variants (25%) were upgraded to invasive lobular carcinoma in surgical excision (4 of 11 cases of LCIS with necrosis [36%] versus 3 of 17 cases of pleomorphic LCIS [18%]).
About one-tenth of solid DCIS diagnosed in core biopsies in the past may represent LCIS variants. These show a 25% upgrade to invasive lobular carcinoma in surgical excision. The distinction of an LCIS variant from DCIS is important because of its implications for radiation therapy, although it may not affect surgical management.
在核心活检中区分导管原位癌(DCIS)和小叶原位癌(LCIS)具有重要的临床意义。小叶原位癌的变体,包括伴有坏死的 LCIS 和多形性 LCIS,具有与实性 DCIS 相似的形态特征,这可能导致误诊。
(1)回顾西北大学范伯格医学院在核心活检中诊断的所有 LCIS 变体,确定在存档的核心活检中,变体 LCIS 被误诊为实性 DCIS 的频率,以及(2)确定在手术切除中升级为浸润性癌或 DCIS 的频率。
选择西北大学范伯格医学院 2001 年 1 月至 2005 年 12 月期间进行的、主要为无浸润的实性 DCIS 的连续核心活检进行 E-钙黏蛋白染色。LCIS 的修订诊断基于 E-钙黏蛋白阴性和形态。然后,从所有原始或修订诊断为多形性 LCIS 或伴有坏死的 LCIS 的核心活检中,估计 LCIS 变体升级的频率。
在 75 例实性 DCIS 中,10 例(13.3%)重新分类为 LCIS,包括 9 种变体(5 例多形性 LCIS,4 例伴有坏死的 LCIS)和 1 例经典 LCIS。28 例患者构成了所有 LCIS 变体病例的整个群体(包括重新分类和最初诊断的病例)。7 例 LCIS 变体患者(25%)在手术切除中升级为浸润性小叶癌(LCIS 伴有坏死的 11 例中有 4 例[36%],多形性 LCIS 的 17 例中有 3 例[18%])。
过去在核心活检中诊断的大约十分之一的实性 DCIS 可能代表 LCIS 变体。这些在手术切除中升级为浸润性小叶癌的比例为 25%。LCIS 变体与 DCIS 的区分很重要,因为它对放射治疗有影响,尽管它可能不会影响手术治疗。